Match each clinical presentation of a urogynecologic condition with the most appropriate therapeutic intervention, taking into account the patient's specific comorbidities.
- A 62-year-old woman with bothersome urgency urinary incontinence and a known history of narrow-angle glaucoma.Prescribe a beta-3 adrenergic receptor agonist (e.g., mirabegron)
- A 58-year-old woman with sudden, uncontrollable urges to void whose blood pressure is consistently mm Hg despite multi-drug therapy.Prescribe a muscarinic receptor antagonist (e.g., oxybutynin)
- A 65-year-old postmenopausal woman with involuntary urine leakage exclusively during exercise, accompanied by severe vaginal dryness and dyspareunia.Initiate topical vaginal estrogen therapy
- A 71-year-old woman with long-standing diabetes mellitus presenting with continuous, small-volume urine dribbling and a post-void residual volume of mL.Educate on clean intermittent self-catheterization
Answer
The correct matches pair the patient with narrow-angle glaucoma to a beta-3 agonist, the patient with severe hypertension to a muscarinic antagonist, the patient with postmenopausal atrophy to topical vaginal estrogen, and the patient with diabetic neurogenic bladder to clean intermittent catheterization.
The correct matches require applying pharmacological knowledge and understanding specific contraindications. Narrow-angle glaucoma precludes anticholinergic use, making beta-3 agonists the drug of choice for overactive bladder. Conversely, uncontrolled hypertension precludes the use of beta-3 agonists, making anticholinergics safer. Hypoestrogenism contributing to stress incontinence and vaginal atrophy is best managed with topical estrogen. Finally, overflow incontinence from a neurogenic bladder (diabetic neuropathy) requires mechanical emptying via catheterization rather than pharmacotherapy.
Step-by-Step Solution
Key Concept
Pharmacologic and non-pharmacologic management of urinary incontinence syndromes based on specific patient comorbidities.